Posted by Michael Wonder on 28 Jun 2023
FDA approves Pfizer’s Ngenla, a long-acting once weekly treatment for paediatric growth hormone deficiency
28 June 2023 - New, longer-acting treatment offers option to reduce the frequency of injections for children with growth hormone deficiency from daily to once weekly.
Pfizer and OPKO Health announced today that the US FDA has approved Nngenla (somatrogon-ghla), a once weekly, human growth hormone analog indicated for treatment of paediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone.
